Aims and background: Erlotinib approval was supported by the positive results of a large
multicentric phase III trial (BR. 21 study) that included 10% Asiatic patients and the …

BACKGROUND: Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …

Background: A randomized trial carried out by Shepherd et al. in patients with advanced or
metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over …

Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …

8111 Background: Skin rash has been associated with increased activity of erlotinib in
retrospective analyses and plasma levels of erlotinib are lower in current vs former or non …

7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …

Objective This study is to analyze the data of Chinese subpopulation in the Tarceva Lung
Cancer Survival Treatment Study (TRUST-China) which was a global Phase IV study …

Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …

Aims: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been
demonstrated in patients with advanced non‐small‐cell lung cancer (NSCLC). Tarceva lung …